Physician profile
Danielle E Bowen
NPI 1780874297
$4,122.52
in general payments reported to CMS, 2019-2025
45 companies · $893 in 2025
The $893 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $433 · 2022: $422 · 2023: $1,486 · 2024: $889 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,081 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,081.16 |
| Education | $185.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $357.28 | 2022-2025 | Trodelvy |
| Sobi, INC | $332.49 | 2022-2024 | |
| Daiichi Sankyo INC. | $314.10 | 2021-2025 | Enhertu, Datroway |
| Regeneron Healthcare Solutions, INC. | $307.34 | 2022-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $220.19 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $190.03 | 2022-2025 | Darzalex, Imbruvica, Erleada |
| Eisai INC. | $187.64 | 2021-2025 | |
| Stryker Corporation | $162.64 | 2025 | Optablate |
| Pfizer INC. | $157.06 | 2022-2025 | |
| Abbvie INC. | $154.99 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $138.31 | 2021-2024 | Lynparza |
| Seagen INC. | $126.41 | 2021-2023 | Padcev, Tivdak |
| Incyte Corporation | $106.55 | 2022-2024 | Monjuvi, Jakafi |
| Novartis Pharmaceuticals Corporation | $106.26 | 2023-2024 | |
| Stemline Therapeutics INC. | $90.61 | 2023-2024 | Orserdu |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $88.21 | 2021-2025 | Blenrep, Ojjaara, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $85.10 | 2023-2024 | Ninlaro, Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $75.26 | 2022-2023 | Opdivo |
| Genzyme Corporation | $67.74 | 2023-2025 | |
| Lilly USA, LLC | $59.34 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Legend Biotech USA INC. | $57.71 | 2025 | Carvykti |
| Astellas Pharma US INC | $57.57 | 2021-2025 | Padcev, Xospata |
| Bayer Healthcare Pharmaceuticals INC. | $55.39 | 2021-2023 | |
| Amgen INC. | $54.95 | 2022-2023 | Kyprolis |
| Morphosys, US INC. | $52.16 | 2022-2024 | Monjuvi |
| Mirati Therapeutics, INC. | $45.97 | 2023-2024 | Krazati |
| Genentech USA, INC. | $44.79 | 2021-2024 | Alecensa, Tecentriq, Rozlytrek |
| Boston Scientific Corporation | $37.97 | 2024 | |
| Acrotech Biopharma INC. | $35.50 | 2024-2025 | Beleodaq |
| Celgene Corporation | $34.53 | 2022-2023 | Pomalyst |
| Karyopharm Therapeutics INC. | $31.56 | 2023-2024 | Xpovio |
| Exelixis INC. | $29.56 | 2021-2023 | Cabometyx |
| Servier Pharmaceuticals LLC | $25.00 | 2025 | |
| Amarin Pharma, INC. | $24.70 | 2021 | |
| Beone Medicines USA, INC. | $24.26 | 2025 | Tevimbra |
| Adc Therapeutics America, INC. | $23.46 | 2022 | |
| Foundation Medicine, INC. | $23.40 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $22.08 | 2021 | |
| Puma Biotechnology, INC. | $19.48 | 2023 | |
| Alexion Pharmaceuticals, INC. | $18.93 | 2024 | Ultomiris |
| Blueprint Medicines Corporation | $18.87 | 2022 | |
| Agios Pharmaceuticals, INC. | $17.14 | 2023 | Pyrukynd |
| Aveo Pharmaceuticals, INC. | $16.91 | 2023 | Fotivda |
| Myovant Sciences INC. | $11.60 | 2021 | |
| Novo Nordisk INC | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.